

## Barrett's oesophagus Committee meeting 8

**Date:** 13/04/2022

**Location:** Virtual meeting

**Minutes:** Final

**NICE** National Institute for  
Health and Care Excellence

<b>Committee members present:</b>		
John Primrose (Chair)		(Present for notes 1-5)
Massimiliano Di Pietro (Topic adviser)		(Present for notes 1-5)
Stephen Brinkworth		(Present for notes 1-5)
Kieran Foley		(Present for notes 1-5)
Helen Griffiths		(Present for notes 1-5)
Gaius Longcroft-Wheaton		(Present for notes 1-5)
Sophie Nelson		(Present for notes 1-5)
Christopher Penniston		(Present for notes 1-5)
Alexander Phillips		(Present for notes 1-5)
Nigel Trudgill		(Present for notes 1-5)

<b>In attendance:</b>		
Amy Crisp	NGC Senior Project Manager	(Present for notes 1-5)
Annette Mead	NICE Editor	(Present for notes 1-5)
Muksitur Rahman	NGC Health Economist	(Present for notes 1-5)
Gill Ritchie	NGC Guideline Lead	(Present for notes 1-5)
Melina Vasileiou	NGC Senior Research Fellow	(Present for notes 1-5)
Joanna Perkin	NICE Editor	(Present for notes 1-5)
Maheen Qureshi	NGC Research Fellow	(Present for notes 1-5)

<b>Apologies:</b>	
Victoria Axe	NICE Guideline Commissioning Manager
Tom Crosby	Committee member
Stephen Deed	NGC Information Specialist
James Gossage	Committee member

Lina Gulhane	NGC Head of Information Specialists
Philip Kaye	Committee member

### **1. Welcome and objectives for the meeting**

The Chair welcomed the Committee members and attendees to the eighth meeting on Barrett's oesophagus.

The Chair informed the Committee that apologies had been received. These are noted above.

### **2. Confirmation of matter under discussion, and declarations of interest**

The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were endoscopic therapies alone and in combination, endoscopic and radiological staging techniques and non endoscopic surveillance.

The Chair asked everyone to verbally declare any new interests.

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

The Chair and a senior member of the Developer's team noted that the following members would not participate in a part of the meeting:

- Nigel Trudgill is unable to participate in discussion of endoscopic therapies alone or in combination (Stage 1 adenocarcinoma).

### **3. Evidence reviews**

MQ, MV and MR presented the following evidence reviews to the committee:

- 4.1 Different endoscopic therapies alone or in combination (Barrett's)
- 4.2 Different endoscopic therapies alone or in combination (Stage 1)

The committee discussed the evidence and made draft recommendations on all reviews.

### **4. CDEs**

MV presented the following CDEs to the committee for their edits and revisions:

- 3.1 Endoscopic and radiological staging techniques (diagnostic accuracy)

- |   |
|---|
| <ul style="list-style-type: none"><li>• 2.2a Non endoscopic surveillance</li><li>• 2.2b Non endoscopic surveillance (diagnostic accuracy)</li></ul> |
| <b>5. Any other business</b>  |
| None.   |

**Date of next meeting:** 26/05/2022

**Location of next meeting:** Virtual meeting